{"docstore/metadata": {"20d66688-47f3-4313-87be-be1c2021432a": {"doc_hash": "b209523b8b85d596f73a167f1e129544af6d463a3b633bb56f16bd5682169378"}, "9c538274-f475-4384-86f5-78233abebabe": {"doc_hash": "3e9f3608cb6fc69f3ddfd8a67081ef2024ee65ccb3470252486090110b94e17d"}, "768fe1a6-1bb5-40bd-a13d-d75596590565": {"doc_hash": "3d634aa806c7724b522b68f316962656ca273d9ffd980c7bb7b68cda22f39009"}, "168eab52-f66c-496f-94a7-d23715babcb4": {"doc_hash": "cb7d18cb08b0585563bd856326c73c7a0a072224b3f60ab2aaf009100ca2455c"}, "bb73c905-19e1-44b0-8b66-445c34f5707e": {"doc_hash": "62eff2cc31c182c73ee7cd436211bb3d68580e913f3a963542d9a82c03c11331"}, "1e0c8467-c596-4443-9710-622110af240b": {"doc_hash": "6f4f938aaaab465a78589ddac44840154428fee57726a095388c108cb42a0353"}, "d4e7affb-568c-41d7-9aac-9785b47d5dd6": {"doc_hash": "eb9a5cb0810bfd490754c8f67324edcceb7c65f31feb59e2d19a697d9d0f6bce"}, "e5a88c36-1677-4fa2-86c5-390369765c27": {"doc_hash": "f0b008fa3ac635a352c78d5b494ade8b446ed1a298733816fb94c2481bceb6a9"}, "ad851039-64c8-44f7-a1ad-b38e87a7b0d9": {"doc_hash": "be49c1a3a5c2cf01d223001a6fe28082bb67ef3d1169716ea827bede4dd6350a"}, "4373bb81-c9b8-4c92-95ce-76cc1c010833": {"doc_hash": "5387b20ba2045bd6c846fbf531d409b3f2afa9156eafdeeb19b020cc7d66eba7"}, "6405c6e2-c817-4c0c-8718-7ef4be59cae2": {"doc_hash": "a6cac583a904f583fd3a1fc2251f7e27cfeee67278aa4a4ab4aadf3fcdeae382"}, "0ab13df3-3653-4390-8568-a09d49b18160": {"doc_hash": "b613ae52a3b610dfae4078e143c2750c96e1241874cce0e7cf4a568ddf92682d"}, "d743a3e1-be95-4ca7-bbaa-ea1fa5b323bf": {"doc_hash": "f108349d8aac72d5a5f02f03ed16e4ce8ff6b0d6d964aa8de4c1c80622fffab9"}, "75a48f68-d3ea-44f5-93ff-a6fb743d4b8f": {"doc_hash": "0ffb033ef4af0e8e69a71b9c113754b0cb7780d5f6e68628f563cf622286283e"}, "6e48e197-7dd6-4b03-8ed6-6dd9522d00ad": {"doc_hash": "b5fd9a9309db856609c53a8b1213c377112a00a90fd14a2c7c394699a7ed049a"}, "b52d7e56-6f63-4c94-8094-a6de4efa9060": {"doc_hash": "87e66ec2f0e753579b37a2a6c9e13c15339813958e5d2e3b0bcd3f3a64723bcf"}, "8852844f-1169-4da3-9743-4419d087efd8": {"doc_hash": "c6421ecf5f291deba50408f5d1a5d8dc605440624feb551538e69abf93aac43f"}, "87467443-2b0d-445d-91be-e4337fce923f": {"doc_hash": "de9c010cbbbd7f1c8f978956ae54d19ef9538428005446b81e284a05b1c5037c"}, "0c8411cf-21c6-413d-9208-ed902e581381": {"doc_hash": "8164fee91c22a73b449d4ec155b8002d5163dc0d2d8db0c25f3b2f04fda5d16c"}, "ddc271ed-8cf6-49b0-8375-03bcc01cee19": {"doc_hash": "0164cd1141c521cba70c4fc96dd79b9a8a7cf7d952cd0b23172c0f844cfcc8f7"}, "46bd4546-9d98-46da-b10f-80715be01c48": {"doc_hash": "102f7f8c032f1d6df050561a234fe94df9d001b63b5bdb4851f3c20e3b6a58fb"}, "f6fb2a37-bbfc-4bb8-bebe-a637ce5ebd0e": {"doc_hash": "d5c017720f0c18611f9d8e83d5615cfe37dd1e58d892973bddfeab223da1ee12"}, "d8f48cd3-41f0-4a52-9c51-774422d2c46d": {"doc_hash": "3e497f7e276b968ace14959a955082720b866d0f3c50d6b9fc7a346b8c8c8f6a"}, "0d31ead9-bc15-47d9-bf0c-ca9fd982b25e": {"doc_hash": "18fe6f6d6b3477d274b514d317dda3f4789d2592b45729278bbed02822206067"}, "8bf5a5ed-27ad-4a17-9530-51f829065983": {"doc_hash": "b209523b8b85d596f73a167f1e129544af6d463a3b633bb56f16bd5682169378", "ref_doc_id": "20d66688-47f3-4313-87be-be1c2021432a"}, "cd9e8eb8-abf3-4004-b033-175d074335fb": {"doc_hash": "3e9f3608cb6fc69f3ddfd8a67081ef2024ee65ccb3470252486090110b94e17d", "ref_doc_id": "9c538274-f475-4384-86f5-78233abebabe"}, "1d2e83fc-cf67-47fc-a960-edc16451c4e1": {"doc_hash": "d1553b235433b21dc71b3aefe56f257a98bcfbd0dd9a51cf4ccad78bbed20144", "ref_doc_id": "768fe1a6-1bb5-40bd-a13d-d75596590565"}, "f5659831-35e8-49d0-8467-0d98bb68a156": {"doc_hash": "5530f0bdfd3b0a592666a9e343885aa4e6f56d3f414e094477fe275122030687", "ref_doc_id": "168eab52-f66c-496f-94a7-d23715babcb4"}, "7a173655-d83e-4751-b4a3-1e6ee578b235": {"doc_hash": "8a4ceca4065786a17775322691ab3f97b203c5815bbbb2875f6a43a301031545", "ref_doc_id": "bb73c905-19e1-44b0-8b66-445c34f5707e"}, "d86649a1-122d-413b-bcff-6124ceedaba6": {"doc_hash": "6f4f938aaaab465a78589ddac44840154428fee57726a095388c108cb42a0353", "ref_doc_id": "1e0c8467-c596-4443-9710-622110af240b"}, "daff4439-8c5a-44f4-b08f-21dc5edc4cad": {"doc_hash": "32de3cd0a484a3591390764f0315d34c900cdd9fb93d0955bc5c9fca8dc797fb", "ref_doc_id": "d4e7affb-568c-41d7-9aac-9785b47d5dd6"}, "0cade14b-1464-401d-84ad-a462e45aad9c": {"doc_hash": "4e663ad2158e1807ac9795a7694066ed4022155027c7f0f94ce750f05c5611e0", "ref_doc_id": "e5a88c36-1677-4fa2-86c5-390369765c27"}, "8424e2cc-abd6-4ad3-97f3-9bb5a99023a8": {"doc_hash": "dab5f5cd8b3fa2b6b6eda830d6d1d41924de3df6c06fc88be4a09ed2c611d627", "ref_doc_id": "ad851039-64c8-44f7-a1ad-b38e87a7b0d9"}, "98a6a66b-0482-4ca3-a54d-46b76168a4f3": {"doc_hash": "d2f778e8eb68ffa13df021d68d51a5b9a8ad7b3bfade11edbce923df4d51a711", "ref_doc_id": "4373bb81-c9b8-4c92-95ce-76cc1c010833"}, "90ef56f7-8874-44b9-accf-a7608e5d1fbf": {"doc_hash": "ce11a706f0d8b28daad20d7098c30119b50b9e02e88edc20327bc959970ce40e", "ref_doc_id": "6405c6e2-c817-4c0c-8718-7ef4be59cae2"}, "3676b2c9-6dcb-43c2-ab84-f04eb6c7c8f1": {"doc_hash": "4126564aa111eebe385ac15474a36705aa7787d6000fae2915715a2881413150", "ref_doc_id": "0ab13df3-3653-4390-8568-a09d49b18160"}, "521f825c-9954-49f9-81ce-3b63fc7ea13c": {"doc_hash": "02ff7d05426144bebcc997438e025b8bfb1b0ede4ce00a301f1f33df4bd8ab2a", "ref_doc_id": "d743a3e1-be95-4ca7-bbaa-ea1fa5b323bf"}, "c80d1a30-0ae4-4a5b-9eaf-c81fb7e56021": {"doc_hash": "57c6dbbf121b71d8adece163f2c5a6e61986088dda22c38efc86edecef9304f3", "ref_doc_id": "75a48f68-d3ea-44f5-93ff-a6fb743d4b8f"}, "92676cef-d9b1-456c-a07f-d2452b2d9eb6": {"doc_hash": "2ef5e70284bf5091c462500c961cb55f9d39298ba4f5b477012a3271e9e93edb", "ref_doc_id": "6e48e197-7dd6-4b03-8ed6-6dd9522d00ad"}, "a4c80e47-73da-4377-8f51-4fd29ffe9f91": {"doc_hash": "a8adcf362e188dc5aa24f7e414f11be3529018c85d0928a70cb507b0b468bfbe", "ref_doc_id": "b52d7e56-6f63-4c94-8094-a6de4efa9060"}, "5854a204-43c3-4afa-a4f5-1060e04c39dc": {"doc_hash": "0bd506c5944ef6f06005c5f3df97b24cd777ad925e4166b96cce772340783bf0", "ref_doc_id": "8852844f-1169-4da3-9743-4419d087efd8"}, "986de56b-1e69-4406-9a7f-43647f7b08a0": {"doc_hash": "2e147df8ed07ed17275537dae7d4d4f212eacf51cc8fe540846820244e278a62", "ref_doc_id": "87467443-2b0d-445d-91be-e4337fce923f"}, "3ed6b74b-1b6e-471d-82b5-ecbbdca7c888": {"doc_hash": "6e2af5809747b25fea4c2d25daa86e6fc43a5ef8e965b76fe9f69fea74ce38d1", "ref_doc_id": "0c8411cf-21c6-413d-9208-ed902e581381"}, "301df447-be2a-4966-a231-c5316008a922": {"doc_hash": "37e78acb15c8fbdff7929fb45ce9564e488f899ae2f0469385cd719273632045", "ref_doc_id": "ddc271ed-8cf6-49b0-8375-03bcc01cee19"}, "2115d382-c930-4064-b870-b6d8625e51d3": {"doc_hash": "3bdc3a2a6e216f9cae0b6d1d52bbfdcc6e1ff021849cb5ce8e030c5f5afc6566", "ref_doc_id": "46bd4546-9d98-46da-b10f-80715be01c48"}, "e409c04f-ac27-4bf6-b24b-42d935a0b930": {"doc_hash": "865da2f95572a9a96b8f94897a4edbad26f2e6cc9430141f3d5c8dc6668e9351", "ref_doc_id": "f6fb2a37-bbfc-4bb8-bebe-a637ce5ebd0e"}, "843c463e-5c07-4763-9350-1ccb338018af": {"doc_hash": "65bbc60326da65731a2e454d594d1e3d52453ffe4bf60fb1f4c96fa94608ead9", "ref_doc_id": "d8f48cd3-41f0-4a52-9c51-774422d2c46d"}, "967b3849-d036-41df-bda5-af90d10301ee": {"doc_hash": "afb4adb867453bb44d5e54a08cc1bea0a8bc434d6007c08705c7167ad4c3c1d9", "ref_doc_id": "0d31ead9-bc15-47d9-bf0c-ca9fd982b25e"}}, "docstore/data": {"8bf5a5ed-27ad-4a17-9530-51f829065983": {"__data__": {"id_": "8bf5a5ed-27ad-4a17-9530-51f829065983", "embedding": null, "metadata": {"page_label": "1", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "20d66688-47f3-4313-87be-be1c2021432a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "b209523b8b85d596f73a167f1e129544af6d463a3b633bb56f16bd5682169378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd9e8eb8-abf3-4004-b033-175d074335fb", "node_type": "1", "metadata": {}, "hash": "16cec2ce7a951343b1720365a5092b3306e26ca3dfae238d1af7130ba02e237b", "class_name": "RelatedNodeInfo"}}, "text": "Supplementary Appendix\nThis appendix has been provided by the authors to give readers additional information about their work.\nSupplement to: Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal \njunction cancer. N Engl J Med 2021;384:1191-203. DOI: 10.1056/NEJMoa2032125", "start_char_idx": 0, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd9e8eb8-abf3-4004-b033-175d074335fb": {"__data__": {"id_": "cd9e8eb8-abf3-4004-b033-175d074335fb", "embedding": null, "metadata": {"page_label": "2", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9c538274-f475-4384-86f5-78233abebabe", "node_type": "4", "metadata": {"page_label": "2", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "3e9f3608cb6fc69f3ddfd8a67081ef2024ee65ccb3470252486090110b94e17d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bf5a5ed-27ad-4a17-9530-51f829065983", "node_type": "1", "metadata": {"page_label": "1", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "b209523b8b85d596f73a167f1e129544af6d463a3b633bb56f16bd5682169378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d2e83fc-cf67-47fc-a960-edc16451c4e1", "node_type": "1", "metadata": {}, "hash": "a35a1a55a4bf2d3c811132aba22686e10947fdcc362ed23199050418c9d24ed6", "class_name": "RelatedNodeInfo"}}, "text": "1 Supplementary Appendix \nThis appendix has been provided by the authors to give readers additional information about \ntheir work. Supplement to: Kelly R, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected \nEsophageal or Gastroesophageal Junction Cancer  \nContents \nList of Sites and Investigators ....................................................................................................................... 2\nAdditional Key Inclusion and Exclusion Criteria ......................................................................................... 5\nTreatment Allocation, Blinding, and Randomization ................................................................................... 6\nCensoring Summary for Disease-free Survival ............................................................................................ 6\nAssessment of Distant Metastasis\u2013free Survival and Health-related Quality of Life ................................... 7\nAnalysis Populations ..................................................................................................................................... 9\nTable S1. Prior Chemotherapy and Radiotherapy Treatment. .................................................................... 10\nTable S2. Demographics and Baseline Clinical Characteristics by Time from Complete Resection to \nRandomization. ........................................................................................................................................... 12\nTable S3. Subsequent Therapies. ................................................................................................................ 14\nTable S4. Exposure. .................................................................................................................................... 15\nTable S5. Treatment-related Adverse Events with Potential Immunologic Etiology. ................................ 16\nFigure S1. CONSORT Diagram for Patient Disposition. ........................................................................... 17\nFigure S2. Post Hoc Assessment of Disease-free Survival by Subgroups. ................................................. 18\nFigure S3. Least Squares Means (95% CI) Changes from Baseline for Nivolumab and Placebo in the \nPatient-reported Outcomes Population. ...................................................................................................... 19\nFigure S4. FACT-E GP5 (\u201cI am bothered by side effects of treatment\u201d) Item Values. .............................. 22\nReferences ................................................................................................................................................... 23", "start_char_idx": 0, "end_char_idx": 2695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d2e83fc-cf67-47fc-a960-edc16451c4e1": {"__data__": {"id_": "1d2e83fc-cf67-47fc-a960-edc16451c4e1", "embedding": null, "metadata": {"page_label": "3", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "768fe1a6-1bb5-40bd-a13d-d75596590565", "node_type": "4", "metadata": {"page_label": "3", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "3d634aa806c7724b522b68f316962656ca273d9ffd980c7bb7b68cda22f39009", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd9e8eb8-abf3-4004-b033-175d074335fb", "node_type": "1", "metadata": {"page_label": "2", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "3e9f3608cb6fc69f3ddfd8a67081ef2024ee65ccb3470252486090110b94e17d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5659831-35e8-49d0-8467-0d98bb68a156", "node_type": "1", "metadata": {}, "hash": "41d65c1cd24c330ad03b4bcf7d3c47fe27f8415bfdd2f6ac31fcb5e19b74e511", "class_name": "RelatedNodeInfo"}}, "text": "2 List of Sites and Investigators\nPrincipal investigators for each site who participated in this trial. \nArgentina:  Luciana Bellaquero, Marcela Carballido, Javier Castillo, Guillermo Mendez, Juan \nO\u2019Connor, Felipe Palazzo \nAustralia:  Victoria Atkinson, Stephen Clarke, Kynan Feeney, Mathew George, Adnan Nagrial, \nLouise Nott, Nimit Singhal, Andrew Strickland, Matthew Wong \nBelgium:  Joelle Collignon, Karen Geboes, Jean-Charles Goeminne, Marc Peeters, Eric Van \nCutsem, Marc Van Den Eynde \nBrazil:  Thais Almeida, Giovanni Bariani, Arinilda Bragagnoli, Fernanda Capareli, Gustavo \nFernandes, Fabio Franke, Ana Caroline Gelatti, Eduardo Moraes, Andre Murad, Fernando Vieira \nCanada:  Thierry Alcindor, Elena Elimova, Derek Jonker, Sheryl Koski, Howard Lim, Stephanie \nSnow, Mark Vincent \nChina:  Keneng Chen, Qixun Chen, Wentao Fang, Jian Hu, Shuoyan Liu, Lijie Tan, Zhentao Yu, \nKuaile Zhao \nCzech Republic:  Bohuslav Melichar, Radim Nemecek, Milan Vosmik \nDenmark:  Marianne Nordsmark \nFrance:  Thierry Andre, Francois Ghiringhelli, Olivier Glehen, Rosine Guimbaud, Astrid Li\u00e8vre, \nPierre Michel, Laurent Mineur, Guillaume Piessen \nGermany:  Michael Bitzer, Sylvie Lorenzen, Markus Moehler, Jorge Urrico Riera-\nKnorrenschild, Marianne Sinn, Michael Stahl, Peter Thuss-Patience, Thomas Zander \nHong Kong:  Ka On Lam \nHungary:  Peter Arcosy, Erika Hitre \nIreland:  Gregory Leonard, Patrick Morris, Derek Power \nIsrael:  Irit Lando Ben-Aharon, Ravit Geva, Ayala Hubert, Gali Perl, Einat Shacham Shmueli", "start_char_idx": 0, "end_char_idx": 1504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5659831-35e8-49d0-8467-0d98bb68a156": {"__data__": {"id_": "f5659831-35e8-49d0-8467-0d98bb68a156", "embedding": null, "metadata": {"page_label": "4", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "168eab52-f66c-496f-94a7-d23715babcb4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "cb7d18cb08b0585563bd856326c73c7a0a072224b3f60ab2aaf009100ca2455c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d2e83fc-cf67-47fc-a960-edc16451c4e1", "node_type": "1", "metadata": {"page_label": "3", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "d1553b235433b21dc71b3aefe56f257a98bcfbd0dd9a51cf4ccad78bbed20144", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a173655-d83e-4751-b4a3-1e6ee578b235", "node_type": "1", "metadata": {}, "hash": "79028cbc54946d1e21a891a93e727041d7235f6f23b5dba63a7da284c2c8b3c5", "class_name": "RelatedNodeInfo"}}, "text": "3 Italy:  Maria Di Bartolomeo \nJapan:  Hideo Baba, Keisho Chin, Yuichiro Doki, Hiroki Hara; Masao Hosokawa; Ken Kato, \nHisahiro Matsubara, Yuji Miura, Masaru Morita, Satoru Motoyama, Shoji Natsugoe, Morihito \nOkada, Eiji Oki, Yoshihiro Ota, Masanobu Takahashi, Akihito Tsuji, Kazuhiro Yoshida \nMexico:  German Calderillo Ruiz, Jorge Alberto Guadarrama Orozco, Fidel Huitzil, Lorena \nUrzua Flores \nNetherlands:  Judith de Vos-Geelen, Cecile Grootscholten, Geke Hospers \nPoland:  Katarzyna Behrendt, Jaroslaw Kuzdzal, Jacek Mackiewicz, Tomasz Olesinski, Grzegorz \nWallner \nRomania:  Adina Croitoru, Ingrid Iordan, Anca Mihailov, Michael Schenker, Andrei Ungureanu \nRussia:  Sergey Dvoretskiy, Evgeny Levchenko, Somasundaram Subramanian, Alexey Tryakin \nSingapore:  Matthew Ng \nSouth Korea:  Hye Ryun Kim, Sung Bae Kim \nSpain:  Maria Alsina, Enrique Aranda, Montserrat Blanco, Antonio Cubillo \nSwitzerland:  Viviane Hess, Christian Weisshaupt \nTaiwan:  Chih-Hung Hsu, Chen-Yuan Lin, Chia-Jui Yen \nTurkey:  Salim Basol Tekin, Mustafa Ozguroglu \nUnited Kingdom:  Andrew Bateman, Sarah Ngan, Paul Shaw \nUnited States:  Jaffer Ajani, Ari Baron, Thomas Bauer, Johanna Bendell, Daniel Catennaci, \nJennifer Chuy, Jeffrey Clark, James Cleary, Allen Cohn, Sarah Davis, Crystal Denlinger, Tarek \nEldawy, Josephine Feliciano, Laura Goff, Martin Gutierrez, Aiwu Ruth He, Blair Jobe, Ronan \nKelly, Andrew H. Ko, Heinz Lenz, Bruce Lin, Albert Lockhart, Charles Lopez, Sam Lubner, \nSudhir Manda, Paul Oberstein, Haeseong Park, Vijay Patel, Eirini Pectasides, Stuart Salmon,", "start_char_idx": 0, "end_char_idx": 1555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a173655-d83e-4751-b4a3-1e6ee578b235": {"__data__": {"id_": "7a173655-d83e-4751-b4a3-1e6ee578b235", "embedding": null, "metadata": {"page_label": "5", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bb73c905-19e1-44b0-8b66-445c34f5707e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "62eff2cc31c182c73ee7cd436211bb3d68580e913f3a963542d9a82c03c11331", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5659831-35e8-49d0-8467-0d98bb68a156", "node_type": "1", "metadata": {"page_label": "4", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "5530f0bdfd3b0a592666a9e343885aa4e6f56d3f414e094477fe275122030687", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d86649a1-122d-413b-bcff-6124ceedaba6", "node_type": "1", "metadata": {}, "hash": "9aa72b591f3c1f0d653cecfb48455469bd28e6529c2a64578fa27cdbd338b91d", "class_name": "RelatedNodeInfo"}}, "text": "4 Joel Saltzman, Usman Shah, Veena Shankaran, Bijoy P. Telivala, Hope Uronis, David Wang, \nSyed Zafar", "start_char_idx": 0, "end_char_idx": 101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d86649a1-122d-413b-bcff-6124ceedaba6": {"__data__": {"id_": "d86649a1-122d-413b-bcff-6124ceedaba6", "embedding": null, "metadata": {"page_label": "6", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1e0c8467-c596-4443-9710-622110af240b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "6f4f938aaaab465a78589ddac44840154428fee57726a095388c108cb42a0353", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a173655-d83e-4751-b4a3-1e6ee578b235", "node_type": "1", "metadata": {"page_label": "5", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "8a4ceca4065786a17775322691ab3f97b203c5815bbbb2875f6a43a301031545", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daff4439-8c5a-44f4-b08f-21dc5edc4cad", "node_type": "1", "metadata": {}, "hash": "e0709739475d8ff3a21273e00dc2a9c4adc42d393c189041a892c69057aa1cdf", "class_name": "RelatedNodeInfo"}}, "text": "5 Additional Key Inclusion and Exclusion Criteria  \n1.Inclusion criteria \n\uf0b7Complete resection must have been performed within 4 to 16 weeks prior to \nrandomization\n\uf0b7Patients must have been disease free as documented by a complete physical \nexamination and imaging studies within 4 weeks prior to randomization \n\uf0b7Tumor tissue from the resected site of disease must have been provided for \nbiomarker analyses, including tumor cell programmed death ligand 1 (PD-L1) \nstatus \n2.Exclusion criteria \n\uf0b7Patients with cervical esophageal carcinoma and those who did not receive \nconcurrent chemoradiotherapy prior to surgery or who only received \nchemotherapy or only radiation prior to surgery, and those with stage IV \nresectable disease\n\uf0b7Patients with previous malignancies unless a complete remission was achieved at \nleast 5 years prior to trial entry and no additional therapy was required or \nanticipated (exceptions included, but were not limited to, non-melanoma skin \ncancers, in situ bladder cancer, in situ colon cancers, in situ cervical \ncancers/dysplasia, or in situ breast carcinoma) \n\uf0b7Patients with active, known, or suspected autoimmune disease, except for those \nwith diabetes mellitus or hypothyroidism requiring only hormone replacement or \nskin disorders (vitiligo, psoriasis, or alopecia) that did not require systemic \ntreatment, or conditions that were not expected to recur in the absence of an \nexternal trigger", "start_char_idx": 0, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daff4439-8c5a-44f4-b08f-21dc5edc4cad": {"__data__": {"id_": "daff4439-8c5a-44f4-b08f-21dc5edc4cad", "embedding": null, "metadata": {"page_label": "7", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d4e7affb-568c-41d7-9aac-9785b47d5dd6", "node_type": "4", "metadata": {"page_label": "7", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "eb9a5cb0810bfd490754c8f67324edcceb7c65f31feb59e2d19a697d9d0f6bce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d86649a1-122d-413b-bcff-6124ceedaba6", "node_type": "1", "metadata": {"page_label": "6", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "6f4f938aaaab465a78589ddac44840154428fee57726a095388c108cb42a0353", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cade14b-1464-401d-84ad-a462e45aad9c", "node_type": "1", "metadata": {}, "hash": "b9f0c845fd2207a0ae788dfb6e05f65f4acc3a710148f115b995c8e3dc8bc1f9", "class_name": "RelatedNodeInfo"}}, "text": "6 \uf0b7Patients who required systemic treatment with either corticosteroids (>10 \nmg/daily) or other immunosuppressive medications within 14 days of trial drug \nadministration, except for inhaled or topical steroids, or adrenal replacement \nsteroids equivalent to more than 10 mg of prednisone\n\uf0b7Patients with symptomatic interstitial lung disease, human immunodeficiency \nvirus or acquired immunodeficiency syndrome, and toxicities associated with \nprior anticancer therapy, as well as those who had received anti\u2013programmed \ndeath (PD)-1, anti\u2013PD-L1, anti\u2013PD-L2, anti-CD137, or anti\u2013CTLA-4 antibody \ntherapies \nTreatment Allocation, Blinding, and Randomization \nThe treatment allocation list was generated by the sponsor. The web registration system was \nimplemented by a third party and ensured that the treatment assignment sequence was concealed \nto the investigator, patient, and sponsor. The study was double blinded; the sponsor, patients, \ninvestigators, and site staff were blinded to treatment allocation. Randomization was performed \nusing interactive (voice/web) response technology with a block size of 3 and was stratified \naccording to tumor cell PD-L1 expression (\u22651% vs. <1% or indeterminate or nonevaluable), \npathologic lymph node status (\u2265ypN1 vs. ypN0), and histology (squamous vs. adenocarcinoma). \nCensoring Summary for Disease-free Survival \nFor patients who remained alive and without recurrence, disease-free survival was censored on \nthe date of last evaluable disease assessment. Patients who started subsequent therapy \n(radiotherapy, surgery, or systemic anticancer therapy) or developed a second primary cancer \nwithout recurrence were censored on the last tumor assessment date prior to the start of \nsubsequent therapy or diagnosis of a second primary cancer. At the clinical data cutoff, 398", "start_char_idx": 0, "end_char_idx": 1821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cade14b-1464-401d-84ad-a462e45aad9c": {"__data__": {"id_": "0cade14b-1464-401d-84ad-a462e45aad9c", "embedding": null, "metadata": {"page_label": "8", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e5a88c36-1677-4fa2-86c5-390369765c27", "node_type": "4", "metadata": {"page_label": "8", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "f0b008fa3ac635a352c78d5b494ade8b446ed1a298733816fb94c2481bceb6a9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daff4439-8c5a-44f4-b08f-21dc5edc4cad", "node_type": "1", "metadata": {"page_label": "7", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "32de3cd0a484a3591390764f0315d34c900cdd9fb93d0955bc5c9fca8dc797fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8424e2cc-abd6-4ad3-97f3-9bb5a99023a8", "node_type": "1", "metadata": {}, "hash": "8b3e24a0ebdfedeeb71e94fd23105a38515658c25762bed71e305d5900197b58", "class_name": "RelatedNodeInfo"}}, "text": "7 (50%) randomized patients were censored for disease-free survival. Most of these patients (n = \n379, 48%) were censored on their last tumor assessment date prior to the start of subsequent \ntherapy or development of a second primary cancer. Of these 379 patients, 310 (39%) were in \nfollow-up, 50 (6%) were receiving treatment, nine (1%) were off study (two lost to follow-up, \nsix withdrawn consent, one other reason), and 10 (1%) developed a second primary cancer. The \nremaining 19 (2%) disease-free survival-censored patients were censored on the date of \nrandomization for lack of an on-study tumor assessment. \nAssessment of Distant Metastasis\u2013free Survival and Health-related Quality of Life \nDistant metastasis\u2013free survival was defined as the time between the date of randomization and \nthe date of first distant recurrence or date of death (whatever the cause), whichever occurred \nfirst. For patients who remained alive and distant recurrence free, distant metastasis\u2013free survival \ndata were censored on the date of last disease assessment. The hazard ratio for distant \nmetastasis\u2013free survival with its corresponding two-sided 95% confidence interval (CI) was \nestimated via a Cox model with treatment group as the only covariate in the model stratified by \nthe three randomization stratification factors. Distant metastasis\u2013free survival for each treatment \ngroup was estimated and plotted using the Kaplan\u2013Meier product-limit method. Median distant \nmetastasis\u2013free survival time was computed using the Kaplan\u2013Meier estimate, and a 95% CI for \nthe median was computed based on a log-log transformation of the survivor function. The CIs for \nthe median distant metastasis\u2013free survival were not adjusted for multiplicity. Distant \nmetastasis\u2013free survival was an exploratory endpoint in the study and was not powered for \nstatistical comparison. \nThe FACT-E (Functional Assessment of Cancer Therapy\u2013Esophageal) questionnaire was \nused to assess the effects of underlying disease and its treatment on health-related quality of life.", "start_char_idx": 0, "end_char_idx": 2048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8424e2cc-abd6-4ad3-97f3-9bb5a99023a8": {"__data__": {"id_": "8424e2cc-abd6-4ad3-97f3-9bb5a99023a8", "embedding": null, "metadata": {"page_label": "9", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ad851039-64c8-44f7-a1ad-b38e87a7b0d9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "be49c1a3a5c2cf01d223001a6fe28082bb67ef3d1169716ea827bede4dd6350a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cade14b-1464-401d-84ad-a462e45aad9c", "node_type": "1", "metadata": {"page_label": "8", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "4e663ad2158e1807ac9795a7694066ed4022155027c7f0f94ce750f05c5611e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98a6a66b-0482-4ca3-a54d-46b76168a4f3", "node_type": "1", "metadata": {}, "hash": "41d3131dd6aceced2fd6f4192d665c165bce3a1968bbbbcf25216732a3efdaef", "class_name": "RelatedNodeInfo"}}, "text": "8 This tool includes the 27-item FACT-General (FACT-G) and an additional 17 items (esophageal \ncancer subscale) specific to esophageal cancer that assess concerns related to swallowing, \nvocalization, breathing, and other symptoms. Thresholds for clinically meaningful change were \n9.5 points for the FACT-E total score, with a sensitivity clinically meaningful change of 13.1 \npoints.1,2\nThe European Quality of Life\u20135 Dimensions (EQ-5D) descriptive system assessed the \noverall health status of patients through the EQ-5D-3L Visual Analogue Scale and Utility Index. \nChanges from baseline of 7 and 0.08 points for the Visual Analogue Scale and Utility Index, \nrespectively, were considered clinically meaningful.3 Longitudinal mixed model analysis was \nused to compare the least squares mean score differences between treatment groups, with a \nseparate analysis being performed for each patient-reported outcome. \nThe impact of missing data on the patient-reported outcomes analysis was analyzed \nwithin each treatment group by review of missing data patterns, reported reasons for missing \ndata, and impact of the patient-reported outcome score prior to drop-out; the review of the \nobserved data concluded that the amount of missing data was limited and was similar in each \ntreatment group. Therefore, for the purposes for conducting the on-treatment MMRM models, a \nmissing at random assumption was reasonable. Completion rates for patient-reported outcome \nmeasures were high for both treatment groups. A review of the missing data did not indicate any \nclear patterns; therefore, no imputation for missing data was performed. A mixed model repeated \nmeasures was used for the analysis of change from baseline; to aid interpretation, the number of \npatients with data at each visit is presented in Figure S3. Additionally, in Figure S4, missing data \nat each visit are presented to allow for the transparent review of the GP5 results.", "start_char_idx": 0, "end_char_idx": 1941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98a6a66b-0482-4ca3-a54d-46b76168a4f3": {"__data__": {"id_": "98a6a66b-0482-4ca3-a54d-46b76168a4f3", "embedding": null, "metadata": {"page_label": "10", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4373bb81-c9b8-4c92-95ce-76cc1c010833", "node_type": "4", "metadata": {"page_label": "10", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "5387b20ba2045bd6c846fbf531d409b3f2afa9156eafdeeb19b020cc7d66eba7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8424e2cc-abd6-4ad3-97f3-9bb5a99023a8", "node_type": "1", "metadata": {"page_label": "9", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "dab5f5cd8b3fa2b6b6eda830d6d1d41924de3df6c06fc88be4a09ed2c611d627", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90ef56f7-8874-44b9-accf-a7608e5d1fbf", "node_type": "1", "metadata": {}, "hash": "58688f8d6aa9f695c041fc3ab472b3945a8417c38bddd310ffc93c920c950911", "class_name": "RelatedNodeInfo"}}, "text": "9 Analysis Populations \n\uf0b7All enrolled patients: All patients who signed an informed consent form and were \nregistered into the interactive web response system \n\uf0b7All randomized patients (efficacy population): All patients who were randomly assigned \nto any treatment group in the trial. This was the primary dataset for analyses of trial \nconduct, trial population, and efficacy \n\uf0b7All treated patients (safety population): All randomly assigned patients who received at \nleast one dose of nivolumab or placebo during the trial. This was the primary dataset for \nanalyses of exposure and safety \n\uf0b7Patient-reported outcomes population: Randomly assigned patients who had an \nassessment at screening/baseline and at least one follow-up assessment", "start_char_idx": 0, "end_char_idx": 742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90ef56f7-8874-44b9-accf-a7608e5d1fbf": {"__data__": {"id_": "90ef56f7-8874-44b9-accf-a7608e5d1fbf", "embedding": null, "metadata": {"page_label": "11", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6405c6e2-c817-4c0c-8718-7ef4be59cae2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "a6cac583a904f583fd3a1fc2251f7e27cfeee67278aa4a4ab4aadf3fcdeae382", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98a6a66b-0482-4ca3-a54d-46b76168a4f3", "node_type": "1", "metadata": {"page_label": "10", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "d2f778e8eb68ffa13df021d68d51a5b9a8ad7b3bfade11edbce923df4d51a711", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3676b2c9-6dcb-43c2-ab84-f04eb6c7c8f1", "node_type": "1", "metadata": {}, "hash": "3329f49edd7094695986c7f11da0646736923894866947e5fd26868b7118b237", "class_name": "RelatedNodeInfo"}}, "text": "10 Table S1. Prior Chemotherapy and Radiotherapy Treatment. \nPrior Chemoradiotherapy Treatment Nivolumab \n(N = 532) Placebo \n(N = 262) \nPatients who received prior concurrent CRT \u2014 no. (%)* 528 (99) 261 (>99) \nChemotherapy \u2014 no. (%)\u2020 \nNeoadjuvant  527 (99) 260 (99) \nCarboplatin/paclitaxel 386 (73) 177 (68) \nCisplatin/fluorouracil 77 (14) 35 (13) \nFluorouracil/oxaliplatin 14 (3) 9 (3) \nOther 50 (9) 39 (15) \nRadiotherapy in prior concurrent CRT \u2014 no. (%)\u2021 528 (99) 261 (>99) \nMedian radiotherapy dosage \u2014 Gray (range)\u2021 45.0 (1.80\u22127560) 45.0 (4.14\u22125040) \nRadiotherapy dosage, Gray \u2014 no. (%)\u2021\u00a7 \n<41.4 66 (12) 26 (10) \n<40 7 (1) 3 (1) \n40\u2013<41.4 59 (11) 23 (9) \n41.4\u201350.4 339 (64) 165 (63) \n>50.4 93 (18) 59 (23) \nNot reported 30 (6) 11 (4) \nCRT denotes chemoradiotherapy.  \n* Includes only regimens related to the latest concurrent CRT followed by complete resection.  \n\u2020 Adjuvant carboplatin/paclitaxel was given to one patient in the nivolumab group, and adjuvant \nfluorouracil/leucovorin/oxaliplatin was given to one patient in the placebo group (protocol \nviolations).", "start_char_idx": 0, "end_char_idx": 1071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3676b2c9-6dcb-43c2-ab84-f04eb6c7c8f1": {"__data__": {"id_": "3676b2c9-6dcb-43c2-ab84-f04eb6c7c8f1", "embedding": null, "metadata": {"page_label": "12", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0ab13df3-3653-4390-8568-a09d49b18160", "node_type": "4", "metadata": {"page_label": "12", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "b613ae52a3b610dfae4078e143c2750c96e1241874cce0e7cf4a568ddf92682d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90ef56f7-8874-44b9-accf-a7608e5d1fbf", "node_type": "1", "metadata": {"page_label": "11", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "ce11a706f0d8b28daad20d7098c30119b50b9e02e88edc20327bc959970ce40e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "521f825c-9954-49f9-81ce-3b63fc7ea13c", "node_type": "1", "metadata": {}, "hash": "513fafaccfd62229a832533ccb057680eaee3251672ebb1a7e4f5f47cbebf488", "class_name": "RelatedNodeInfo"}}, "text": "11 \u2021 Includes the sum of radiotherapies received from the start of concurrent CRT until complete \nresection. Radiotherapy exposure occurred prior to the conduct of the trial and was not under the \ncontrol of the study investigators; dose received was as reported in the case report form and \nfollowing database lock, investigators amended the total dose of radiotherapy for seven patients \nin the <40 Gray group to 41.4\u201350.4 Gray.  \n\u00a7 Percentages are out of 528 nivolumab patients and 261 placebo patients who received prior \nconcurrent CRT followed by complete resection.", "start_char_idx": 0, "end_char_idx": 572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "521f825c-9954-49f9-81ce-3b63fc7ea13c": {"__data__": {"id_": "521f825c-9954-49f9-81ce-3b63fc7ea13c", "embedding": null, "metadata": {"page_label": "13", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d743a3e1-be95-4ca7-bbaa-ea1fa5b323bf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "f108349d8aac72d5a5f02f03ed16e4ce8ff6b0d6d964aa8de4c1c80622fffab9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3676b2c9-6dcb-43c2-ab84-f04eb6c7c8f1", "node_type": "1", "metadata": {"page_label": "12", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "4126564aa111eebe385ac15474a36705aa7787d6000fae2915715a2881413150", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c80d1a30-0ae4-4a5b-9eaf-c81fb7e56021", "node_type": "1", "metadata": {}, "hash": "dadb95cc3ab000dbd7fdca1cedf328843a27087747d4435f9cd58503cf18f6af", "class_name": "RelatedNodeInfo"}}, "text": "12 Table S2. Demographics and Baseline Clinical Characteristics by Time from Complete \nResection to Randomization. \nTime from Complete \nResection to Randomization \n<10 weeks  Time from Complete \nResection to Randomization \n\u226510 weeks  \nNivolumab \n(n = 182) Placebo \n(n = 74) Nivolumab \n(n = 350) Placebo \n(n = 188) \nMedian age (range) \u2014 yr 62.0 (36\u201382) 60.5 (26\u201386) 62.0 (26\u201382) 62.0 (30\u201384) \nMale \u2014 no. (%) 155 (85) 64 (86) 294 (84) 158 (84) \nRace* \u2014 no. (%) \nWhite 128 (70) 53 (72) 304 (87) 163 (87) \nAsian 50 (27) 18 (24) 33 (9) 16 (9) \nECOG PS \u2014 no. (%) \n0 113 (62) 49 (66) 195 (56) 107 (57) \n1 69 (38) 25 (34) 155 (44) 81 (43) \nDisease stage at initial \ndiagnosis \u2014 no. (%) \nII 60 (33) 27 (36) 119 (34) 72 (38) \nIII 122 (67) 47 (64) 229 (65) 116 (62) \nTumor location \u2014 no. (%) \nEC 124 (68) 47 (64) 196 (56) 108 (57) \nGEJC 58 (32) 27 (36) 154 (44) 80 (43) \nHistology \u2014 no. (%) \nSquamous cell carcinoma 77 (42) 24 (32) 78 (22) 51 (27)", "start_char_idx": 0, "end_char_idx": 936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c80d1a30-0ae4-4a5b-9eaf-c81fb7e56021": {"__data__": {"id_": "c80d1a30-0ae4-4a5b-9eaf-c81fb7e56021", "embedding": null, "metadata": {"page_label": "14", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "75a48f68-d3ea-44f5-93ff-a6fb743d4b8f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "0ffb033ef4af0e8e69a71b9c113754b0cb7780d5f6e68628f563cf622286283e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "521f825c-9954-49f9-81ce-3b63fc7ea13c", "node_type": "1", "metadata": {"page_label": "13", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "02ff7d05426144bebcc997438e025b8bfb1b0ede4ce00a301f1f33df4bd8ab2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92676cef-d9b1-456c-a07f-d2452b2d9eb6", "node_type": "1", "metadata": {}, "hash": "3477214daa79e741a1ef5d3464111cea595e5240b805c877429431a300da0a10", "class_name": "RelatedNodeInfo"}}, "text": "13 Adenocarcinoma 105 (58) 50 (68) 271 (77) 137 (73) \nPathologic lymph node status \n\u2265 ypN1 \u2014 no. (%) 99 (54) 43 (58) 206 (59) 109 (58) \nTumor cell PD-L1 expression \u2020\n\u2014 no. (%) \n\u22651% 36 (20) 14 (19) 53 (15) 26 (14) \n<1% 117 (64) 51 (69) 257 (73) 145 (77) \nIndeterminate/nonevaluable 29 (16) 9 (12) 40 (11) 17 (9) \nEC denotes esophageal cancer; ECOG PS, Eastern Cooperative Oncology Group performance \nstatus; GEJC, gastroesophageal junction cancer; PD-L1, programmed death ligand 1.  \n* Other races not shown.  \n\u2020 Tumor cell PD-L1 expression determined from surgical specimen by the PD-L1 IHC 28-8 \npharmDx assay (Dako).", "start_char_idx": 0, "end_char_idx": 618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92676cef-d9b1-456c-a07f-d2452b2d9eb6": {"__data__": {"id_": "92676cef-d9b1-456c-a07f-d2452b2d9eb6", "embedding": null, "metadata": {"page_label": "15", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6e48e197-7dd6-4b03-8ed6-6dd9522d00ad", "node_type": "4", "metadata": {"page_label": "15", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "b5fd9a9309db856609c53a8b1213c377112a00a90fd14a2c7c394699a7ed049a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c80d1a30-0ae4-4a5b-9eaf-c81fb7e56021", "node_type": "1", "metadata": {"page_label": "14", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "57c6dbbf121b71d8adece163f2c5a6e61986088dda22c38efc86edecef9304f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4c80e47-73da-4377-8f51-4fd29ffe9f91", "node_type": "1", "metadata": {}, "hash": "3f8e6ac81356051801b1a30029a19ab96928b7089627f57840bf2969b66415a2", "class_name": "RelatedNodeInfo"}}, "text": "14 Table S3. Subsequent Therapies. \nTherapy Nivolumab \n(N = 532) Placebo \n(N = 262) \nno. of patients (%)\nPatients with any subsequent therapies 157 (30) 111 (42) \nRadiotherapy  43 (8) 41 (16) \nSurgery  28 (5) 20 (8) \nSystemic therapy  125 (23) 89 (34) \nImmunotherapy  4 (<1) 19 (7) \nTargeted therapy 13 (2) 11 (4) \nOther systemic anticancer therapy/chemotherapy 123 (23) 85 (32)", "start_char_idx": 0, "end_char_idx": 378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4c80e47-73da-4377-8f51-4fd29ffe9f91": {"__data__": {"id_": "a4c80e47-73da-4377-8f51-4fd29ffe9f91", "embedding": null, "metadata": {"page_label": "16", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b52d7e56-6f63-4c94-8094-a6de4efa9060", "node_type": "4", "metadata": {"page_label": "16", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "87e66ec2f0e753579b37a2a6c9e13c15339813958e5d2e3b0bcd3f3a64723bcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92676cef-d9b1-456c-a07f-d2452b2d9eb6", "node_type": "1", "metadata": {"page_label": "15", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "2ef5e70284bf5091c462500c961cb55f9d39298ba4f5b477012a3271e9e93edb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5854a204-43c3-4afa-a4f5-1060e04c39dc", "node_type": "1", "metadata": {}, "hash": "4114872626745cae138e794e5b02cc1533d15be18b0e2c6908078536b0a89841", "class_name": "RelatedNodeInfo"}}, "text": "15 Table S4. Exposure. \nVariable Nivolumab* \n(N = 532) Placebo* \n(N = 260) \nMedian duration of treatment (range) \u2014 mo 10.1 (<0.1\u201214.2) 9.0 (<0.1\u201215.0) \nRelative dose intensity \u2014 no. (%) \n\u226590% 459 (86) NA \n70% \u2013 <90% 67 (13) NA \n50% \u2013 <70% 4 (<1) NA \n<50% 2 (<1) NA \n\u22651 dose delay \u2014 no. (%) 226 (42) 113 (43) \nDoses delayed per patient \u2014 no. (%) \n0 306 (58) 147 (57) \n1 148 (28) 68 (26) \n2 51 (10) 30 (12) \n3 17 (3) 9 (3) \n\u22654 10 (2) 6 (2) \nNA denotes not applicable. \n* All randomized patients who received at least one dose of trial treatment (safety population).", "start_char_idx": 0, "end_char_idx": 563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5854a204-43c3-4afa-a4f5-1060e04c39dc": {"__data__": {"id_": "5854a204-43c3-4afa-a4f5-1060e04c39dc", "embedding": null, "metadata": {"page_label": "17", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8852844f-1169-4da3-9743-4419d087efd8", "node_type": "4", "metadata": {"page_label": "17", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "c6421ecf5f291deba50408f5d1a5d8dc605440624feb551538e69abf93aac43f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4c80e47-73da-4377-8f51-4fd29ffe9f91", "node_type": "1", "metadata": {"page_label": "16", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "a8adcf362e188dc5aa24f7e414f11be3529018c85d0928a70cb507b0b468bfbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "986de56b-1e69-4406-9a7f-43647f7b08a0", "node_type": "1", "metadata": {}, "hash": "045f6b9f507aac5e91f046344a8eee3ca27f6dbf7508c350dd2f40bcbd9415e8", "class_name": "RelatedNodeInfo"}}, "text": "16 Table S5. Treatment-related Adverse Events with Potential Immunologic Etiology .\nSelect Treatment-related \nAdverse Events\u2020\u2021  Nivolumab* \n(N = 532) Placebo* \n(N = 260) \nAny Grade Grade 3\u20134 Any Grade Grade 3\u20134 \nno. of patients (%) \nEndocrine 93 (17) 5 (<1) 6 (2) 0 \nGastrointestinal 91 (17) 4 (<1) 40 (15) 3 (1) \nHepatic 49 (9) 6 (1) 18 (7) 4 (2) \nPulmonary 23 (4) 6 (1) 4 (2) 1 (<1) \nRenal 7 (1) 1 (<1) 2 (<1) 0 \nSkin 130 (24) 7 (1) 28 (11) 1 (<1) \n* All randomized patients who received at least one dose of trial treatment (safety population).  \n\u2020 Select treatment-related adverse events are those with potential immunologic etiology that require \nfrequent monitoring/intervention. \n\u2021 Events reported between first dose and 30 days after last dose of trial drug.", "start_char_idx": 0, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "986de56b-1e69-4406-9a7f-43647f7b08a0": {"__data__": {"id_": "986de56b-1e69-4406-9a7f-43647f7b08a0", "embedding": null, "metadata": {"page_label": "18", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "87467443-2b0d-445d-91be-e4337fce923f", "node_type": "4", "metadata": {"page_label": "18", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "de9c010cbbbd7f1c8f978956ae54d19ef9538428005446b81e284a05b1c5037c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5854a204-43c3-4afa-a4f5-1060e04c39dc", "node_type": "1", "metadata": {"page_label": "17", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "0bd506c5944ef6f06005c5f3df97b24cd777ad925e4166b96cce772340783bf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ed6b74b-1b6e-471d-82b5-ecbbdca7c888", "node_type": "1", "metadata": {}, "hash": "f7bb9b6a9be189a662a747492c5157ded76155ab1a3e43b5248de86c5cdd50bf", "class_name": "RelatedNodeInfo"}}, "text": "17 Figure S1. CONSORT Diagram for Patient Disposition.", "start_char_idx": 0, "end_char_idx": 54, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ed6b74b-1b6e-471d-82b5-ecbbdca7c888": {"__data__": {"id_": "3ed6b74b-1b6e-471d-82b5-ecbbdca7c888", "embedding": null, "metadata": {"page_label": "19", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0c8411cf-21c6-413d-9208-ed902e581381", "node_type": "4", "metadata": {"page_label": "19", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "8164fee91c22a73b449d4ec155b8002d5163dc0d2d8db0c25f3b2f04fda5d16c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "986de56b-1e69-4406-9a7f-43647f7b08a0", "node_type": "1", "metadata": {"page_label": "18", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "2e147df8ed07ed17275537dae7d4d4f212eacf51cc8fe540846820244e278a62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "301df447-be2a-4966-a231-c5316008a922", "node_type": "1", "metadata": {}, "hash": "a95053261b728a52e3d490a2f7f93e4fbe53f976d938c59ca42f87c3580315c9", "class_name": "RelatedNodeInfo"}}, "text": "18 Figure S2. Post Hoc Assessment of Disease-free Survival by Subgroups. \nCI denotes confidence interval; CPS, combined positive score; PD-L1, programmed death \nligand 1. \n* 10 patients (seven in the nivolumab group and three in the placebo group) received total \nexposure less than 40 Gray (following database lock, investigators amended the total dose \nof radiotherapy for seven of these patients to 41.4\u201350.4 Gray).", "start_char_idx": 0, "end_char_idx": 418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "301df447-be2a-4966-a231-c5316008a922": {"__data__": {"id_": "301df447-be2a-4966-a231-c5316008a922", "embedding": null, "metadata": {"page_label": "20", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ddc271ed-8cf6-49b0-8375-03bcc01cee19", "node_type": "4", "metadata": {"page_label": "20", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "0164cd1141c521cba70c4fc96dd79b9a8a7cf7d952cd0b23172c0f844cfcc8f7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ed6b74b-1b6e-471d-82b5-ecbbdca7c888", "node_type": "1", "metadata": {"page_label": "19", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "6e2af5809747b25fea4c2d25daa86e6fc43a5ef8e965b76fe9f69fea74ce38d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2115d382-c930-4064-b870-b6d8625e51d3", "node_type": "1", "metadata": {}, "hash": "d5fee9d338de5c260742c718346dd6276c7e4f45870ea5d9ab54da0fda0c74b8", "class_name": "RelatedNodeInfo"}}, "text": "19 Figure S3. Least Squares Means (95% CI) Changes from Baseline for Nivolumab and \nPlacebo in the Patient-reported Outcomes Population. \nA   FACT-E \nDashed lines indicate a clinically meaningful change of 9.5 points, and dotted lines \nindicate a sensitivity score change of 13.1 points.1,2 Error bars indicate 95% confidence \nintervals.", "start_char_idx": 0, "end_char_idx": 337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2115d382-c930-4064-b870-b6d8625e51d3": {"__data__": {"id_": "2115d382-c930-4064-b870-b6d8625e51d3", "embedding": null, "metadata": {"page_label": "21", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "46bd4546-9d98-46da-b10f-80715be01c48", "node_type": "4", "metadata": {"page_label": "21", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "102f7f8c032f1d6df050561a234fe94df9d001b63b5bdb4851f3c20e3b6a58fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "301df447-be2a-4966-a231-c5316008a922", "node_type": "1", "metadata": {"page_label": "20", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "37e78acb15c8fbdff7929fb45ce9564e488f899ae2f0469385cd719273632045", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e409c04f-ac27-4bf6-b24b-42d935a0b930", "node_type": "1", "metadata": {}, "hash": "8715aab0d60febd7336e374f2202c9e81b228ef1824756500839b7f9cdbe1ada", "class_name": "RelatedNodeInfo"}}, "text": "20 B   EQ-5D Visual Analogue Scale\nDashed lines indicate clinically meaningful change (7 points).3 Error bars indicate 95% \nconfidence intervals.", "start_char_idx": 0, "end_char_idx": 145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e409c04f-ac27-4bf6-b24b-42d935a0b930": {"__data__": {"id_": "e409c04f-ac27-4bf6-b24b-42d935a0b930", "embedding": null, "metadata": {"page_label": "22", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f6fb2a37-bbfc-4bb8-bebe-a637ce5ebd0e", "node_type": "4", "metadata": {"page_label": "22", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "d5c017720f0c18611f9d8e83d5615cfe37dd1e58d892973bddfeab223da1ee12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2115d382-c930-4064-b870-b6d8625e51d3", "node_type": "1", "metadata": {"page_label": "21", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "3bdc3a2a6e216f9cae0b6d1d52bbfdcc6e1ff021849cb5ce8e030c5f5afc6566", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "843c463e-5c07-4763-9350-1ccb338018af", "node_type": "1", "metadata": {}, "hash": "f3812027b36965eb13421dbf34d3d144149d70cdb7e03cf6710d385c7effdd1a", "class_name": "RelatedNodeInfo"}}, "text": "21 C   EQ-5D Utility Index Score \nDashed lines indicate clinically meaningful change (0.08 points).3 Error bars indicate \n95% confidence intervals.", "start_char_idx": 0, "end_char_idx": 147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "843c463e-5c07-4763-9350-1ccb338018af": {"__data__": {"id_": "843c463e-5c07-4763-9350-1ccb338018af", "embedding": null, "metadata": {"page_label": "23", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d8f48cd3-41f0-4a52-9c51-774422d2c46d", "node_type": "4", "metadata": {"page_label": "23", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "3e497f7e276b968ace14959a955082720b866d0f3c50d6b9fc7a346b8c8c8f6a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e409c04f-ac27-4bf6-b24b-42d935a0b930", "node_type": "1", "metadata": {"page_label": "22", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "865da2f95572a9a96b8f94897a4edbad26f2e6cc9430141f3d5c8dc6668e9351", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "967b3849-d036-41df-bda5-af90d10301ee", "node_type": "1", "metadata": {}, "hash": "a856985c78eb06c182c30f05541af392e008ee17323eb35384af0428ddebdfcb", "class_name": "RelatedNodeInfo"}}, "text": "22 Figure S4. FACT-E GP5 (\u201cI am bothered by side effects of treatment\u201d) Item Values.", "start_char_idx": 0, "end_char_idx": 84, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "967b3849-d036-41df-bda5-af90d10301ee": {"__data__": {"id_": "967b3849-d036-41df-bda5-af90d10301ee", "embedding": null, "metadata": {"page_label": "24", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0d31ead9-bc15-47d9-bf0c-ca9fd982b25e", "node_type": "4", "metadata": {"page_label": "24", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "18fe6f6d6b3477d274b514d317dda3f4789d2592b45729278bbed02822206067", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "843c463e-5c07-4763-9350-1ccb338018af", "node_type": "1", "metadata": {"page_label": "23", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}, "hash": "65bbc60326da65731a2e454d594d1e3d52453ffe4bf60fb1f4c96fa94608ead9", "class_name": "RelatedNodeInfo"}}, "text": "23 References \n1. Darling G, Eton DT, Sulman J, Casson AG, Celia D. Validation of the functional \nassessment of cancer therapy esophageal cancer subscale. Cancer 2006;107:854-63. \n2. Ringash J, O\u2019Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant \nchanges in patient-reported outcomes. Cancer 2007;110:196-202. \n3. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D \nutility and VAS scores in cancer [published correction appears in Health Qual Life \nOutcomes. 2010;8:4]. Health Qual Life Outcomes 2007;5:70.", "start_char_idx": 0, "end_char_idx": 565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"20d66688-47f3-4313-87be-be1c2021432a": {"node_ids": ["8bf5a5ed-27ad-4a17-9530-51f829065983"], "metadata": {"page_label": "1", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "9c538274-f475-4384-86f5-78233abebabe": {"node_ids": ["cd9e8eb8-abf3-4004-b033-175d074335fb"], "metadata": {"page_label": "2", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "768fe1a6-1bb5-40bd-a13d-d75596590565": {"node_ids": ["1d2e83fc-cf67-47fc-a960-edc16451c4e1"], "metadata": {"page_label": "3", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "168eab52-f66c-496f-94a7-d23715babcb4": {"node_ids": ["f5659831-35e8-49d0-8467-0d98bb68a156"], "metadata": {"page_label": "4", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "bb73c905-19e1-44b0-8b66-445c34f5707e": {"node_ids": ["7a173655-d83e-4751-b4a3-1e6ee578b235"], "metadata": {"page_label": "5", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "1e0c8467-c596-4443-9710-622110af240b": {"node_ids": ["d86649a1-122d-413b-bcff-6124ceedaba6"], "metadata": {"page_label": "6", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "d4e7affb-568c-41d7-9aac-9785b47d5dd6": {"node_ids": ["daff4439-8c5a-44f4-b08f-21dc5edc4cad"], "metadata": {"page_label": "7", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "e5a88c36-1677-4fa2-86c5-390369765c27": {"node_ids": ["0cade14b-1464-401d-84ad-a462e45aad9c"], "metadata": {"page_label": "8", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "ad851039-64c8-44f7-a1ad-b38e87a7b0d9": {"node_ids": ["8424e2cc-abd6-4ad3-97f3-9bb5a99023a8"], "metadata": {"page_label": "9", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "4373bb81-c9b8-4c92-95ce-76cc1c010833": {"node_ids": ["98a6a66b-0482-4ca3-a54d-46b76168a4f3"], "metadata": {"page_label": "10", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "6405c6e2-c817-4c0c-8718-7ef4be59cae2": {"node_ids": ["90ef56f7-8874-44b9-accf-a7608e5d1fbf"], "metadata": {"page_label": "11", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "0ab13df3-3653-4390-8568-a09d49b18160": {"node_ids": ["3676b2c9-6dcb-43c2-ab84-f04eb6c7c8f1"], "metadata": {"page_label": "12", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "d743a3e1-be95-4ca7-bbaa-ea1fa5b323bf": {"node_ids": ["521f825c-9954-49f9-81ce-3b63fc7ea13c"], "metadata": {"page_label": "13", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "75a48f68-d3ea-44f5-93ff-a6fb743d4b8f": {"node_ids": ["c80d1a30-0ae4-4a5b-9eaf-c81fb7e56021"], "metadata": {"page_label": "14", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "6e48e197-7dd6-4b03-8ed6-6dd9522d00ad": {"node_ids": ["92676cef-d9b1-456c-a07f-d2452b2d9eb6"], "metadata": {"page_label": "15", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "b52d7e56-6f63-4c94-8094-a6de4efa9060": {"node_ids": ["a4c80e47-73da-4377-8f51-4fd29ffe9f91"], "metadata": {"page_label": "16", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "8852844f-1169-4da3-9743-4419d087efd8": {"node_ids": ["5854a204-43c3-4afa-a4f5-1060e04c39dc"], "metadata": {"page_label": "17", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "87467443-2b0d-445d-91be-e4337fce923f": {"node_ids": ["986de56b-1e69-4406-9a7f-43647f7b08a0"], "metadata": {"page_label": "18", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "0c8411cf-21c6-413d-9208-ed902e581381": {"node_ids": ["3ed6b74b-1b6e-471d-82b5-ecbbdca7c888"], "metadata": {"page_label": "19", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "ddc271ed-8cf6-49b0-8375-03bcc01cee19": {"node_ids": ["301df447-be2a-4966-a231-c5316008a922"], "metadata": {"page_label": "20", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "46bd4546-9d98-46da-b10f-80715be01c48": {"node_ids": ["2115d382-c930-4064-b870-b6d8625e51d3"], "metadata": {"page_label": "21", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "f6fb2a37-bbfc-4bb8-bebe-a637ce5ebd0e": {"node_ids": ["e409c04f-ac27-4bf6-b24b-42d935a0b930"], "metadata": {"page_label": "22", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "d8f48cd3-41f0-4a52-9c51-774422d2c46d": {"node_ids": ["843c463e-5c07-4763-9350-1ccb338018af"], "metadata": {"page_label": "23", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}, "0d31ead9-bc15-47d9-bf0c-ca9fd982b25e": {"node_ids": ["967b3849-d036-41df-bda5-af90d10301ee"], "metadata": {"page_label": "24", "file_name": "data\\Supplement to Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021.pdf"}}}}